AcelRx Pharmaceuticals 2021 Cash Bonus Plan for Named Executive Officers
AcelRx Pharmaceuticals, Inc. established a 2021 Cash Bonus Plan for its named executive officers, including the CEO, CMO, CFO, and Chief Engineering Officer. The plan sets target bonuses ranging from 35% to 60% of each executive’s 2021 base salary. The CEO’s bonus is based entirely on company objectives, while other executives’ bonuses are split between individual and company performance. Actual bonuses may exceed targets if performance surpasses set goals.
Exhibit 10.18
2021 Cash Bonus Plan Summary
Target bonuses for named executive officers of AcelRx Pharmaceuticals, Inc. (the “Company”) under the 2021 Cash Bonus Plan (the “Plan”) will range from 35% to 60% of such executive’s 2021 base salary. The target bonuses for the Company’s named executive officers for 2021 are as follows:
| Name | Position | Bonus % |
| Vincent Angotti | Chief Executive Officer | 60% |
| Pamela Palmer, M.D., Ph.D. | Chief Medical Officer | 40% |
| Raffi Asadorian | Chief Financial Officer | 40% |
| Badri Dasu | Chief Engineering Officer | 35% |
Mr. Angotti’s cash bonus under the Plan shall be based 100% on the achievement of the 2021 corporate objectives. The cash bonuses under the Plan for all other named executive officers shall be based 40% on the achievement of his or her individual performance goals, as determined by the Board, and 60% on the achievement of the 2021 corporate objectives. The named executive officers’ actual bonuses may exceed 100% of target in the event performance exceeds the predetermined goals.
